Literature DB >> 21873030

Myoclonic astatic epilepsy: an age-dependent epileptic syndrome with favorable seizure outcome but variable cognitive evolution.

Marina Trivisano1, Nicola Specchio, Simona Cappelletti, Vincenzo Di Ciommo, Dianela Claps, Luigi M Specchio, Federico Vigevano, Lucia Fusco.   

Abstract

The objective of the study was to explore clinical, electroencephalography (EEG), neuropsychological features and prognosis of myoclonic-astatic epilepsy (MAE). Of 327 children aged between 1 and 9 years with a diagnosis of generalized epilepsy followed between 2000 and 2008, 18 (5.5%) had MAE. Male significantly predominated (88.9%). Age at onset ranged from 2.3 to 4.9 years (mean 3.6 years). Median follow-up period was 6.3 years. In addition to myoclonic-astatic seizures patients had myoclonic seizures (66.7%), drop attacks (72.2%), head drops (77.8%) absences (88.9%), tonic-clonic generalized seizure (77.8%), tonic seizures (38.9%), non-convulsive status epilepticus (16.7%). Seven patients (38.9%) had an epileptic encephalopathy. At onset, interictal epileptiform and slow abnormalities were recorded, respectively, in 100% and 77.8% of patients. EEG abnormalities disappeared in all patients within 4 years since the onset. At long-term follow-up, two patients developed focal abnormalities typical of rolandic epilepsy and two patients photosensitivity. On neuropsychological testing 66.7% of patients had a normal IQ (mean 81.2±17.0, range 47-105, median 84.5) after a mean period of 4.4 years since the last seizure. Sixteen out of 18 patients remitted within 3.5 years since the onset and in two patients tonic seizures persisted. MAE is generalized childhood epilepsy: although cognitive functions might deteriorate, outcome is good regarding seizures.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873030     DOI: 10.1016/j.eplepsyres.2011.07.021

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  5 in total

1.  Diagnosis switching and outcomes in a cohort of patients with potential epilepsy with myoclonic-atonic seizures.

Authors:  Krista Eschbach; Angela Moss; Charuta Joshi; Katie Angione; Garnett Smith; Amanda Dempsey; Elizabeth Juarez-Colunga; Scott T Demarest
Journal:  Epilepsy Res       Date:  2018-09-24       Impact factor: 3.045

Review 2.  Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.

Authors:  Katherine C Nickels; Michael J Zaccariello; Lorie D Hamiwka; Elaine C Wirrell
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

Review 3.  Treatment of epileptic encephalopathies.

Authors:  Amy McTague; J Helen Cross
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

Review 4.  Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses.

Authors:  Marina Trivisano; Alessandro Ferretti; Costanza Calabrese; Nicola Pietrafusa; Ludovica Piscitello; Giusy Carfi' Pavia; Federico Vigevano; Nicola Specchio
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

Review 5.  Cognitive impairment in childhood onset epilepsy: up-to-date information about its causes.

Authors:  Eun-Hee Kim; Tae-Sung Ko
Journal:  Korean J Pediatr       Date:  2016-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.